State Street SPDR S&P Pharmaceuticals ETF (XPH)
| Assets | $572.35M |
| Expense Ratio | 0.35% |
| PE Ratio | 14.96 |
| Shares Out | 8.25M |
| Dividend (ttm) | $0.27 |
| Dividend Yield | 0.40% |
| Ex-Dividend Date | Sep 21, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 5.97% |
| Volume | 94,705 |
| Open | 67.99 |
| Previous Close | 67.52 |
| Day's Range | 67.73 - 68.96 |
| 52-Week Low | 45.82 |
| 52-Week High | 74.35 |
| Beta | 0.60 |
| Holdings | 65 |
| Inception Date | Jun 19, 2006 |
About XPH
Fund Home PageThe State Street SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund tracks an equal-weighted index of US pharmaceutical companies. XPH was launched on Jun 19, 2006 and is issued by State Street.
Top 10 Holdings
20.32% of assets| Name | Symbol | Weight |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | AMRX | 2.21% |
| Xeris Biopharma Holdings, Inc. | XERS | 2.16% |
| Veradermics, Incorporated | MANE | 2.14% |
| ANI Pharmaceuticals, Inc. | ANIP | 2.11% |
| Viatris Inc. | VTRS | 1.96% |
| Eli Lilly and Company | LLY | 1.96% |
| Definium Therapeutics, Inc. | DFTX | 1.96% |
| Edgewise Therapeutics, Inc. | EWTX | 1.95% |
| Indivior Pharmaceuticals, Inc. | INDV | 1.93% |
| Supernus Pharmaceuticals, Inc. | SUPN | 1.93% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 21, 2026 | $0.04164 | Sep 23, 2026 |
| Jun 22, 2026 | $0.05905 | Jun 24, 2026 |
| Mar 23, 2026 | $0.06095 | Mar 25, 2026 |
| Dec 22, 2025 | $0.11302 | Dec 24, 2025 |
| Sep 22, 2025 | $0.10263 | Sep 24, 2025 |
| Jun 23, 2025 | $0.09587 | Jun 25, 2025 |
Performance
XPH had a total return of 48.76% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.37%.
News
8 ETF Winners in the 'Pay Me Now' Trade
Investors looking for stability should buy these funds focused on companies with strong sales, healthy dividends, and cash flow.
3 Healthcare ETFs to Own in a Choppy Stock Market
Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.
US FDA to review AI-based tool to predict drug-related liver damage
The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for an artificial intelligence-based drug development tool designed to help predict drug-i...
Trump to announce discount drug pricing expansion, White House official says
U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Monday, ...
US FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals
The U.S. Food and Drug Administration launched a pilot program on Monday aimed at allowing the agency to monitor clinical trial data in real time, a step the agency said could cut years from drug ap...
Could pressure to make money faster kill the next lifesaving pill?
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Britain agrees full text of US-UK pharmaceutical trade deal
Britain said on Thursday it had agreed the full text of a U.S.-UK pharmaceutical partnership, setting out terms under which British-made medicines would enter the United States tariff-free.
Britain will spend more on new medicines in exchange for avoiding tariffs on U.K. pharmaceutical exports to the U.S.
The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.
US and UK agree zero-tariffs on pharmaceuticals
The US has agreed to spare the UK from threatened trade tariffs on pharmaceutical products.
UK and US agree zero-tariff pharmaceuticals deal
Agreement also calls for NHS to increase net price it pays for new medicines by 25%
US, UK to agree to zero tariffs on pharmaceuticals, announcement expected, sources say
Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter.
UK and US poised to agree zero-tariffs deal on pharmaceuticals, The Times says
The UK is poised to agree on a major pharmaceuticals deal with the U.S., which will mean zero import tariffs on pharmaceutical products into the U.S. and lead to an increase in NHS spending on medicin...
The Trump administration said it isn't planning to impose tariffs on generic drugs from foreign countries, which make up most of medications dispensed in the U.S.
The administration has been weighing duties for months on a range of products and ingredients in a national-security tariff investigation.
Trump Trade War: New Tariffs on Drugs, Trucks, and Furniture Raise Inflation Risks
President Trump's new tariffs on drugs, trucks, and furniture reignite trade tensions, boosting U.S. manufacturers but raising global costs, pressuring exporters, and adding inflation risks.
Drug Tariffs Are a Sideshow. Trump's Next Move Could Hit Pharma Harder.
What unnerves investors is a lack of clarity on drug pricing.
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
EU, Japan express confidence in capped US tariffs on drugs
The European Union and Japan expressed confidence on Friday that they had secured limits on U.S. tariffs on pharmaceuticals, which President Donald Trump said he would impose next week at a rate of 10...
India's pharma stock crash after Trump's 100% tariff on branded drugs
India's pharmaceutical stocks were jolted on Friday, when President Donald Trump announced a 100% tariff on imported branded and patented drugs, effective October 1. The move sent shockwaves through g...
Trump announces 100% tariffs on pharmaceuticals unless drug makers are building U.S. factories
President Donald Trump announced a raft of new tariffs late Thursday, including a 100% levy on imported pharmaceuticals unless their manufacturers are actively building factories in the U.S.
Trump announces 100% tariff on imports of branded or patented pharmaceuticals from October 1
The United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the U.S., Pre...
U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says
U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says
Trump hints at higher semiconductor tariffs. Companies could dodge them by doing this.
Trump suggested steep chip-industry tariffs are coming, but there could be breaks for companies that invest in the U.S. Specifics are still sparse.
US FDA announces new program to boost domestic drug manufacturing
The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...
Trump threatens drugmakers with 250% tariffs. Here's when higher levies could come.
The latest level of tariffs on the pharmaceutical industry is the highest yet from the president.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Will 2023 be the year that pharma M&A makes a comeback?
A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.
Final Trades: Pharma, Chevron, Uber & more
The "Halftime Report" traders give their top picks to watch for the second half.
Get ready for more merger mania in pharma sector the rest of the year
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Pharma market investments: How ETFs help you dabble in the sector at a modest price
Some health care sector ETFs have exposure to companies like Johnson & Johnson, Pfizer, UnitedHealth
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
Pharma Stocks Poised to Move Higher
Nearby support on the charts suggests that the pharmaceuticals sector could be one to watch over the last few months of 2020.
President Trump signs executive orders aimed at lowering drug prices
CNBC's Meg Tirrell reports President Trump has signed four executive orders aimed at lowering drug prices. They include the U.S. allowing importation of prescription drugs from Canada and other countr...
Trump announces series of executive orders aimed at lowering drug costs
President Donald Trump on Friday signed four executive orders aimed at lowering the high cost of prescription drugs in the United States in what would make sweeping changes to the prescription drug ma...
Where this top-rated financial advisor is finding opportunities in the market now
Hightower Treasury Partners CIO Richard Saperstein outlines the areas of the market where he currently sees opportunity.
What does the investment committee recommend in health care? #AskHalftime
The "Halftime Report" traders answer viewer questions in #AskHalftime.
Mizuho: Smaller companies are leading the way in developing vaccines for infectious diseases
Mara Goldstein of Mizuho discusses the difficulty of developing a vaccine quickly during a virus outbreak, and which large and smaller biotech and drug companies investors should be focused on.
What to Expect From Big Pharma's Earnings
We expect solid results but will be listening for what a reduction in rebating means for sales growth at various firms, among other trends.